Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial

The Lancet Infectious Diseases

Volumn 15, Issue 7, 2015, Pages 785-792

  Arribas, José R ^a   Girard, Pierre Marie ^b   Landman, Roland ^c   Pich, Judit ^d   Mallolas, Josep ^d,q   Martínez Rebollar, María ^d,q   Zamora, Francisco X ^a   Estrada, Vicente ^e   Crespo, Manuel ^f   Podzamczer, Daniel ^g   Portilla, Joaquín ^h   Dronda, Fernando ⁱ   Iribarren, José A ^j   Domingo, Pere ^k   Pulido, Federico ^l   Montero, Marta ^m   Knobel, Hernando ⁿ   Cabié, André ^o   Weiss, Laurence ^p   Gatell, José M ^d,q   Gonzalez Garcia J J ^a   Pena J M ^a   Montes, M L ^a   Bernardino, J I ^a   Estebanez, M ^a   Perez Valero J I ^a   Castro, J M ^a   Mayoral, M ^a   Tellez, M J ^e   Vergas, J ^e   Perez E ^e   Rodrigo, M ^e   Ribera, E ^f   Navarro, J ^f   Tiraboschi, J M ^g   Saumoy, M ^g   Boix, V ^h   Merino, E ^h   Reus, S ^h   Arcaina, P ^h   Giner, L ^h   Moreno, S ⁱ   Casado, J L ⁱ   Moreno, A ⁱ   Perez M J ⁱ   Azkune, H ^j   Rodriguez Arrondo F ^j   von Wichman, M A ^j   Goenaga, M ^j   Rubio, R ^l   de Lagarde, M ^l   Portillo, A ^l   Matarranz, M ^l   Bisbal, O ^l   Mateo, G ^k   Gutierrez M ^k   Munoz J ^k,u   Aldeguer, J L ^m   Cuellar, S ^m   Blanes, M ^m   Salavert, M ^m   Lacruz, J ^m   Gonzalez A ⁿ   Villar, J ⁿ   Lerma, E ⁿ   Arranz, J A ^r   Sanz, J ^r   de Miguel, J ^r   Casas, E ^r   Ocampo, A ^s   Miralles, C ^s   Rodriguez A ^s   Quero, J H ^t   Parra, J ^t   Martinez M A ^t   Vinuesa, D ^t   Pena A ^t   Ferrero, O L ^u   Santamaria J M ^u   Zubero, Z ^u   Baraia Etxaburu, J ^u   Ibarra, S ^u   Troya, J ^v   Ryan, P ^v   Pedreira, J ^w   Castro, M A ^w   Lopez S ^w   Vazquez P ^w   Garcia D ^x   Beleta, H ^x   Arnaiz, J A ^x   Manea, M ^p   Batisse, D ^p   Abel, S ^y   Pierre Francois S ^y   Yeni P ^c   Papot, E ^c   Julia, Z ^c   Force, G ^z   Duvivier, C ^aa   Durant, J ^ab   Froguel, E ^ac   de Truchis, P ^ad   Berthe H ^ad   Zucman, D ^ae   Amat, K ^af   more..

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HÔPITAL SAINT ANTOINE   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j HOSPITAL DONOSTIA   (Spain)

^k HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^l HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^m HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁿ HOSPITAL DEL MAR   (Spain)

^o CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^p HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^q HOSPITAL CLÍNIC   (Spain)

^r HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^s HOSPITAL XERAL CÍES   (Spain)

^t HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^u HOSPITAL DE BASURTO   (Spain)

^v HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^w HOSPITAL JUAN CANALEJO   (Spain)

^x Hospital Universitario San Cecilio ^*  (Spain)

^y Departement d'Anesthesie Reanimation   (France)

^z Institut Hospitalier Franco Britannique   (France)

^aa HÔPITAL NECKER ENFANTS MALADES   (France)

^ab CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^ac Centre hospitalier de Lagny Marne la Vallee   (France)

^ad RAYMOND POINCARÉ HOSPITAL   (France)

^ae FOCH HOSPITAL   (France)

^af France coordinating centre   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; RITONAVIR; VIRUS RNA;

ADULT; ADVERSE OUTCOME; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE; FEMALE; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SPAIN; SYSTEMIC DISEASE; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; VIRUS INHIBITION; VIRUS LOAD; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; HIV INFECTIONS; IMMUNOLOGY; INTENTION TO TREAT ANALYSIS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PROCEDURES; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INTENTION TO TREAT ANALYSIS; LAMIVUDINE; LOPINAVIR; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; VIRAL LOAD;

EID: 84937521152     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00096-1     Document Type: Article

References (17)

1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2015, Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services USA, Washington, DC.
2. Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection. JAMA 2014, 312:410. for the International Antiviral Society-USA Panel.
3. Guidelines. Version 7.1. November 2014 2014, European AIDS Clinical Society, European AIDS Clinical Society, Brussels.
4. Cahn P, Andrade-Villanueva J, Arribas JR, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis 14: 572-80.
5. Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014, 384:1942-1951.
6. Stellbrink HJ, Pulik P, Szlavik J, et al. Maraviroc (MVC) dosed once daily with darunavir/ritonavir (DRV/r) in a 2 drug-regimen compared to emtricitabine/tenofovir (TDF/FTC) with DRV/r; 48-week results from MODERN (Study A4001095). AIDS 2014: 20th International AIDS Conference; Melbourne, Australia; July 20-25, 2014. Abstr TUAB0101.
7. Di Giambenedetto S, Fabbiani M, Colafigli M, et al. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for Treatment Simplification, ATLAS pilot study). J Antimicrob Chemother 2013, 68:1364-1372.
8. Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, et al. Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. J Int AIDS Soc 2014, 17(4 suppl 3):19808.
9. Perez-Molina JA, Rubio R, Rivero A, et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis 2015, for the GESIDA 7011 Study Group, published online June 1. http://dx.doi.org/10.1016/S1473-3099(15)70137-4.
10. Newcombe RG Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998, 17:873-890.
11. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010, 24:223-230.
12. Martínez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010, 24:1697-1707.
13. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010, 24:2365-2374.
14. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008, 22:F1-F9. for the OK04 Study Group.
15. Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antivir Ther 2010, 15:227-233.
16. Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2003, 48:176-182.
17. Margolis DA, Brinson CC, Smith GH, et al. Cabotegravir and rilpivirine as two-drug oral maintenance therapy: LATTE week 96 results. 2015 Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; Feb 23-26, 2015. Abstr 554LB.